Show simple item record

dc.contributor.authorGlerup, Mia
dc.contributor.authorRypdal, Veronika Gjertsen
dc.contributor.authorArnstad, Ellen Dalen
dc.contributor.authorEkelund, Maria
dc.contributor.authorPeltoniemi, Suvi
dc.contributor.authorAalto, Kristiina
dc.contributor.authorRygg, Marite
dc.contributor.authorToftedal, Peter
dc.contributor.authorNielsen, Susan
dc.contributor.authorFasth, Anders
dc.contributor.authorBerntson, Lillemor
dc.contributor.authorNordal, Ellen Berit
dc.contributor.authorHerlin, Troels
dc.date.accessioned2020-02-18T12:16:10Z
dc.date.available2020-02-18T12:16:10Z
dc.date.issued2019-02-14
dc.description.abstract<i>Objectives</i> - This study assessed the long‐term course, remission rate and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset in a population‐based setting from the early biologic era.<p><p> <i>Methods</i> - A total of 510 consecutive cases of JIA with disease onset between 1997 and 2000 from defined geographic regions in Denmark, Norway, Sweden and Finland were prospectively included in this 18‐year cohort study. At the follow‐up visit, patient‐reported, demographic and clinical data were collected.<p><p> <i>Results</i> - The study included 434 (85%) of the 510 eligible JIA participants. The mean age ± SD was 24.0 ± 4.4 years. The median juvenile arthritis disease activity (JADAS71) score was 1.5 (IQR 0‐5), with the ERA category of JIA having the highest median score, 4.5 (IQR 1.5–8.5) (P=0.003). In this cohort, 46% still had active disease, and 66 (15%) were treated with synthetic disease‐modifying anti‐rheumatic drugs and 84 (19%) with biologics. Inactive disease indicated by JADAS71 <1 was seen in 48% of participants. Clinical remission off medication (CR) was documented in 33% of the participants with high variability among the JIA categories. CR was most often seen in persistent oligoarticular and systemic arthritis and least often in ERA (P<0.001).<p><p> <i>Conclusions</i> - A high prevalence of the JIA cohort did not achieve CR despite new treatment options during the study period. The ERA category showed the worst outcomes and, in general, there is still a high burden of disease in adulthood for JIA.en_US
dc.descriptionThis is the peer reviewed version of the following article: Glerup, M., Rypdal, V., Arnstad, E. D., Ekelund, M., Peltoniemi, S., Aalto, K., ...Herlin, T. (2019). Long‐term outcomes in juvenile idiopathic arthritis: 18 years of follow‐up in the population‐based Nordic Juvenile Idiopathic Arthritis (JIA) cohort. <i>Arthritis Care and Research, ?</i>(?), ?. , which has been published in final form at <a href=https://doi.org/10.1002/acr.23853>https://doi.org/10.1002/acr.23853</a> . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.en_US
dc.identifier.citationGlerup M, Rypdal VG, Arnstad Ed, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T. Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort.. Arthritis care & research. 2019en_US
dc.identifier.cristinIDFRIDAID 1770458
dc.identifier.doi10.1002/acr.23853
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/10037/17416
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalArthritis care & research
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright © 1999-2019 John Wiley & Sons, Inc. All rights reserveden_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleLong-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort.en_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record